Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.00 (0.00%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

HOLD
HOLD
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

PAST TOP PICK
PAST TOP PICK
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

PARTIAL BUY
PARTIAL BUY
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

DON'T BUY
DON'T BUY
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

PARTIAL BUY
PARTIAL BUY
July 9, 2018

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

Show full opinionHide full opinion

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

HOLD
HOLD
July 5, 2018

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Show full opinionHide full opinion

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

WATCH
WATCH
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

BUY
BUY
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

TOP PICK
TOP PICK
May 30, 2018

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Show full opinionHide full opinion

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

PAST TOP PICK
PAST TOP PICK
May 28, 2018

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Show full opinionHide full opinion

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

DON'T BUY
DON'T BUY
May 28, 2018

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Show full opinionHide full opinion

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

DON'T BUY
DON'T BUY
May 24, 2018

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Show full opinionHide full opinion

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

DON'T BUY
DON'T BUY
May 9, 2018

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

Show full opinionHide full opinion

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

BUY
BUY
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Showing 16 to 30 of 90 entries